92
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment

, , &
Pages 10173-10183 | Published online: 22 Dec 2021

References

  • Xu S, Tang L, Li X, Fan F, Liu Z. Immunotherapy for glioma: current management and future application. Cancer Lett. 2020;476:1–12. doi:10.1016/j.canlet.2020.02.002
  • Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(suppl_4):iv1–iv86. doi:10.1093/neuonc/noy131
  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
  • Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
  • Ruff M, Kizilbash S, Buckner J. Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development. Expert Rev Anticancer Ther. 2020;20(5):355–363. doi:10.1080/14737140.2020.1757440
  • Oberoi RK, Parrish KE, Sio TT, et al. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 2016;18(1):27–36. doi:10.1093/neuonc/nov164
  • Ontario Health. 5-Aminolevulinic Acid Hydrochloride (5-ALA)-guided surgical resection of high-grade gliomas: a health technology assessment. Ont Health Technol Assess Ser. 2020;20(9):1–92.
  • Raucher D. Tumor targeting peptides: novel therapeutic strategies in glioblastoma. Curr Opin Pharmacol. 2019;47:14–19. doi:10.1016/j.coph.2019.01.006
  • Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108(1):11–27. doi:10.1007/s11060-011-0793-0
  • Chen X, Yan Y, Zhou J, et al. Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients. Ann Transl Med. 2019;7(20):541. doi:10.21037/atm.2019.09.126
  • Caragher S, Chalmers AJ, Gomez-Roman N. Glioblastoma’s next top model: novel culture systems for brain cancer radiotherapy research. Cancers. 2019;11(1):44. doi:10.3390/cancers11010044
  • Gupta K, Burns TC. Radiation-induced alterations in the recurrent glioblastoma microenvironment: therapeutic implications. Front Oncol. 2018;8:503. doi:10.3389/fonc.2018.00503
  • Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186. doi:10.1038/s41571-020-00447-z
  • Huang L, Wang D, Feng Z, et al. Inhibition of intermedin (Adrenomedullin 2) suppresses the growth of glioblastoma and increases the antitumor activity of temozolomide. Mol Cancer Ther. 2021;20(2):284–295. doi:10.1158/1535-7163.mct-20-0619
  • Singh RR, Reindl KM. Glutathione S-Transferases in Cancer. Antioxidants. 2021;10(5). doi:10.3390/antiox10050701
  • Farmohammadi A, Arab-Yarmohammadi V, Ramzanpour R. Association analysis of rs1695 and rs1138272 variations in GSTP1 gene and breast cancer susceptibility. Asian Pac J Cancer Prev. 2020;21(4):1167–1172. doi:10.31557/apjcp.2020.21.4.1167
  • Cui J, Li G, Yin J, et al. GSTP1 and cancer: expression, methylation, polymorphisms and signaling (Review). Int J Oncol. 2020;56(4):867–878. doi:10.3892/ijo.2020.4979
  • Pourkeramati A, Zare Mehrjardi E, Dehghan Tezerjani M, Seifati SM. Association of GSTP1, GSTT1 and GSTM1 gene variants with coronary artery disease in Iranian population: a Case-Control Study. Int J Gen Med. 2020;13:249–259. doi:10.2147/ijgm.s252552
  • Bushra MU, Rivu SF, Sifat AE, et al. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh. Mol Biol Rep. 2020;47(9):7073–7082. doi:10.1007/s11033-020-05771-2
  • Pasqualetti F, Gonnelli A, Cantarella M, et al. Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy. Invest New Drugs. 2018;36(2):340–345. doi:10.1007/s10637-017-0516-2
  • Liu JY, Liu QM, Li LR. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer. Genet Mol Res. 2015;14(3):10331–10337. doi:10.4238/2015.August.28.19
  • Bai M, Li ZG, Ba Y. Influence of KDR genetic variation on the efficacy and safety of patients with chemotherapy refractory metastatic CRC who received apatinib treatment. Int J Gen Med. 2021;14:1041–1055. doi:10.2147/ijgm.s300968
  • Wang LM, Banu MA, Canoll P, Bruce JN. Rationale and clinical implications of fluorescein-guided supramarginal resection in newly diagnosed high-grade glioma. Front Oncol. 2021;11:666734. doi:10.3389/fonc.2021.666734
  • Mudassar F, Shen H, O’Neill G, Hau E. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Exp Clin Cancer Res. 2020;39(1):208. doi:10.1186/s13046-020-01724-6
  • Ballas ZK. The 2018 Nobel prize in physiology or medicine: an exemplar of bench to bedside in immunology. J Allergy Clin Immunol. 2018;142(6):1752–1753. doi:10.1016/j.jaci.2018.10.021
  • Serventi J, Behr J. Surgery and evidence-based treatments in patients with newly diagnosed high-grade glioma. Semin Oncol Nurs. 2018;34(5):443–453. doi:10.1016/j.soncn.2018.10.009
  • Panciani PP, Giordana MT, Gallone S, et al. Blood-tissue analysis of TP53 polymorphisms and survival of patients with glioma. J Neurosurg Sci. 2021;65(1):8–13. doi:10.23736/s0390-5616.18.04284-4
  • Guo X, Zhang M, Li Q, et al. Evaluation of genetic variants in MIR3142HG in susceptibility to and prognosis of glioma. Am J Clin Oncol. 2020;43(1):1–8. doi:10.1097/coc.0000000000000587
  • Zhou L, Dong S, Deng Y, et al. GOLGA7 rs11337, a polymorphism at the microRNA binding site, is associated with glioma prognosis. Mol Ther Nucleic Acids. 2019;18:56–65. doi:10.1016/j.omtn.2019.08.006
  • Rezaei M, Saadat M. Association between GSTP1 Ile105Val genetic polymorphism and dependency to heroin and opium. Biochem Genet. 2018;57:214–221. doi:10.1007/s10528-018-9885-2
  • Hajdinák P, Szabó M, Kiss E, et al. Genetic polymorphism of GSTP-1 affects cyclophosphamide treatment of autoimmune diseases. Molecules. 2020;25(7):1542. doi:10.3390/molecules25071542
  • Yuan ZJ, Zhou WW, Liu W, et al. Association of GSTP1 and RRM1 polymorphisms with the response and toxicity of gemcitabine-cisplatin combination chemotherapy in Chinese patients with non-small cell lung cancer. Asian Pac J Cancer Prev. 2015;16(10):4347–4351. doi:10.7314/apjcp.2015.16.10.4347
  • Lv H, Han T, Shi X, et al. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer. Med Oncol. 2014;31(8):86. doi:10.1007/s12032-014-0086-5
  • Dong X, Sun R, Wang J, et al. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer. Biochem Pharmacol. 2020;182:114289. doi:10.1016/j.bcp.2020.114289
  • Ferracini AC, Lopes-Aguiar L, Lourenço GJ, et al. GSTP1 and ABCB1 polymorphisms predicting toxicities and clinical management on carboplatin and paclitaxel-based chemotherapy in ovarian cancer. Clin Transl Sci. 2021;14(2):720–728. doi:10.1111/cts.12937
  • Yang F, Gao B, Chen W, et al. Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer. Medicine. 2018;97(41):e12364. doi:10.1097/md.0000000000012364
  • Liu X, Tan N, Liao H, et al. High GSTP1 inhibits cell proliferation by reducing Akt phosphorylation and is associated with a better prognosis in hepatocellular carcinoma. Oncotarget. 2018;9(10):8957–8971. doi:10.18632/oncotarget.23420
  • Tjiong R, Stavrinou P, Röhn G, et al. Heterogeneity of human gliomas: Glutathione-S-Transferase expression profile during disease progression and under systemic therapy. Anticancer Res. 2019;39(4):1795–1805. doi:10.21873/anticanres.13286
  • Liu LQ, Feng LF, Nan CR, Zhao ZM. CREB3L1 and PTN expressions correlate with prognosis of brain glioma patients. Biosci Rep. 2018;38(3). doi:10.1042/bsr20170100